For US Healthcare Providers Only

For US Healthcare Providers Only

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

TOP

IMPORTANT SAFETY INFORMATION

Indication

Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history

Important Safety Information for Makena
(hydroxyprogesterone caproate injection)

  • Do not use Makena in women with any of the following conditions:

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

Navigating COVID-19

As you work through the evolving guidance from the CDC in response to the COVID-19 pandemic, please know our team at Makena Care Connection remains available to support your office and your patients.

If you have concerns of therapy disruptions for your patients, please call Makena Care Connection. Your Care Manager can discuss options such as changing the shipping location, exploring home healthcare administration, or troubleshooting any potential shipping delays. Makena Care Connection can be reached at 1-800-847-3418 (M–F, 8AM–8PM ET) or by emailing info@makenacareconnection.com.

FDA Approved Status

There may be some confusion in the healthcare community about the current status of Makena. At this time, it is important to know that Makena’s approval and product label remain unchanged. The product continues to remain available to patients and prescribers.

To learn more about current medical society guidelines, you can visit the American College of Obstetricians and Gynecologists and/or the Society for Maternal-Fetal Medicine website(s).

If you have any questions, we welcome you to contact AMAG Pharmaceuticals at 1-877-411-2510 or by emailing medinfoUS@covispharma.com.

©2020 AMAG Pharmaceuticals, Inc. All rights reserved. PP-MKN-US-00647 10/20